Bin Chen, PhD
 |
Bin Chen, Ph.D.
BS, MS (Nanjing); PhD (Leuven-Belgium)
Associate Professor of Pharmaceutical Sciences
Director, Graduate Program in Pharmacology/Toxicology
Email: b.chen@usp.edu
|
Research Interests
Light-based Tumor Targeting and Imaging
Upon absorption of a certain wavelength light, some compounds can be activated to emit fluorescence and/or generate cytotoxic reactive oxygen species. The combination of laser light and photosensitizing compounds is currently being used for the diagnosis and treatment of various diseases in clinic. My lab focuses on studying and developing this light-based technology for cancer therapy (photodynamic therapy) and imaging (photodetection).
One of my major research interests is to elucidate the mechanisms involved in photodynamic therapy. Over the past years, we have been successfully employing photodynamic therapy as a tumor vascular targeting modality. Our current research focus is on understanding how photodynamic stimulus affects tumor vascular structures and functions using various biochemical, microscopic and imaging techniques.
To achieve effective and specific tumor targeting and imaging, the photosensitizing agent should be selectively accumulated in the target tissue. We have systemically studied the distribution of some current photosensitizing agents and are trying to further improve their tumor selectivity through drug delivery system formulation and targeting moiety conjugation.
Publications
He C, Agharkar P, Chen B. Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after verteporfin-mediated photodynamic therapy. Pharm Res. 2008, 25: 1873-80.
Chen B, Crane C, He C, Gondek D, Agharkar P, Savellano M, Hoopes PJ, Pogue BW. Disparity in vascular response to verteporfin-mediated vascular-targeting therapy between prostate tumor interior versus peripheral vasculature. Int J Cancer. 2008, 123: 695-701.
Chen B, Pogue BW, Luna J, Hardman R, Hoopes PJ, Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism and therapeutic implications. Clin Cancer Res. 2006, 10: 917-23.
Gibbs SL, Chen B, O’Hara JA, Hoopes PJ, Hasan T, Pogue BW. Protoporphyrin IX level correlates with number of mitochondria, but increases in production correlate with tumor cell size. Photochem Photobiol. 2006, 82: 1334-41.
Chen B, Pogue BW, Hoopes PJ, Hasan T. Combining vascular and cellular targeting regimens enhances the therapeutic effect of photodynamic therapy. Int J Radiat Oncol Biol Phys. 2005, 61: 1216-26.
Chen B, Pogue BW, Zhou X, O’Hara JA, Solban N, Demidenko E, Hoopes PJ, Hasan T. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res. 2005, 11: 720-7.
Chen B, Pogue BW, Goodwin IA, O’Hara JA, Wilmot CM, Hutchins JE, Hoopes PJ, Hasan T. Blood flow dynamics following photodynamic therapy with verteporfin in the RIF-1 tumor. Radiat Res. 2003, 160: 452-459.
Chen B, Busan A, Landuyt W, Ni Y, Gaspar R, Roskams T, De Witte P. Potentiation of photodynamic therapy with hypericin by mitomycin C in the RIF-1 mouse tumor model. Photochem Photobiol. 2003, 78: 278-282.
Pogue BW, O'Hara JA, Demidenko E, Wilmot CM, Goodwin IA, Chen B, Swartz HM, Hasan T. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Res. 2003, 63: 1025-33.
Chen B, Roskams T, De Witte P. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem Photobiol. 2002, 76: 509-13.
Chen B, Roskams T, Xu Y, Agostinis P, De Witte P. Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int J Cancer. 2002, 98: 284-90.
Chen B, Xu Y, Roskams T, Delaey E, Agostinis P, Vandenheede JR, De Witte P. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer. 2001, 93: 275-82.
Chen B, De Witte PA. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett. 2000, 150: 111-17.